CANNABIDIVARIN (CBDV)

WHAT IS CANNABIDIVARIN (CBDV)?

Cannabidivarol or CBDV is another name used to refer to one of the Cannabinoids in the class of Cannabidivarin known as Cannabidivarin. It is one of the non-psychoactive Cannabinoids found within the medical cannabis. Being a non-psychoactive agent, it is not capable of producing an effect on the mind or mental processes. By implication, it does not change brain function neither does it result in alterations in perception, mood, consciousness, cognition, or behavior. More so, its chemical structure does not allow it to interact with the CB1 receptors in the human brain.

Cannabidivarin is one out of over 120 cannabinoids identified from the Cannabis plant capable of modulating the physiological activity of cannabis or marijuana. It has Cannabidiol as its homolog except for CBDV has on its side chain, a short of two methyl (CH2) groups. However, the two compounds have been tested to have demonstrated anticonvulsant activity both in animal and human models and are demonstrating promising clinical trial results. (CBDV) was probably first reported in a benzene extract from a Thai cannabis variety referred to as “Meao” by Shoyama, et al., in 1977.  However, it was identified for the first time in 1969 by Vollner et al.

CBDV as a naturally-occurring phytocannabinoid occurs in small traces in certain strains of the cannabis plant. Phytocannabinoid is one of the compounds with many bioactive molecules of the complex mixture of the Cannabis plant. They can either come in neutral forms or as acid precursors. CBDV can be developed into THCV if exposed to acidic conditions. THCV is the shortened form of Tetrahydrocannabivarin which is also a compound in cannabis that has the ability to offer a unique array of effects and medical benefits that makes it different from other cannabinoids such as THC and CBD. Both THCV and CBDV are derived from the same cannabinoid through the combination of divarinolic acid and geranyl phosphate.

There seem to be lack of medical research on CBDV although recently, scientists are beginning to pick interest in its research. Notwithstanding, the lack of much studies on the compound may be responsible for the low demand. However, from the body of few available researches, it has been discovered that indicas from India, Pakistan, and Mexico will have higher levels of CBDV.

HOW IT WORKS

CBDV has been shown to inhibit the activity of diacylglycerol (DAG) lipase-α, the primary enzyme responsible for the synthesis of the endocannabinoid, 2-arachidonoylglycerol (2-AG). Since CBDV is similar to CBD (Cannabidiol) structurally, there are possibilities that it won’t cause the euphoric high associated with high-THC cannabis.

THERAPEUTIC BENEFITS

  • Belonging to the class of Phytocannabinoids, Cannabidivarin is a candidate for therapeutic applications except its usefulness is limited if it exhibits CB receptor inverse agonist activity.

  • Nevertheless, CBDV has a neurochemical pathway thereby rendering it anti-epileptic, anti-nausea and anti-convulsive.

  • Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and CBD, activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro and have potential for the treatment of neuronal hyperexcitability (Iannotti et al., 2014).

  • Cannabidivarin is capable of rescuing memory defects with neurological defects.

INTERESTING FACTS

Cannabidivarin can be considered as a treatment for HIV Neurophatic pain.

REFERENCES

  1. Amada N, Yamasaki Y, Williams CM, Whalley BJ: Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PeerJ. 2013 Nov 21;1:e214. doi: 10.7717/peerj.214. eCollection 2013. [ PubMed:24282673 ]
  2. Shoyama, Y., Hirano, H., Makino, H., Umekita, N., Nishioka, I., 1977. Cannabis. X. The isolation and structures of four new propyl cannabinoid acids, tetrahydrocannabivarinic acid, cannabidivarinic acid, cannabichromevarinic acid and cannabigerovarinic acid, from Thai cannabis, FMeao variant_. Chemical and Pharmaceutical Bulletin 25 (9), 2306–2311.
  3. Tetrahedron Letters . 10 (3): 145–147. 
  4. Vollner, L.; Bieniek, D.; Korte, F. (1969-01-01). “Haschisch XX11XIX. Mitteillung: F. von Spulak, U. Claussen, H.-W. Fehlhaber und F. Korte, Tetrahedron 24, 5379 (1968).: Cannabidivarin, ein neuer Haschisch-Inhaltsstoff”.

Leave a Comment

Your email address will not be published. Required fields are marked *